Progressive multifocal leukoencephalopathy in a patient with multiple myeloma: a case report and analysis of the FDA adverse event reporting system

Elise Jonasson*, Ronald Antulov, Per Trøllund Pedersen, Tobias Sejbæk

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

37 Downloads (Pure)

Abstract

This paper demonstrates a case of progressive multifocal leukoencephalopathy (PML) in a patient with multiple myeloma (MM) treated with nine different MM therapies. This case report contributes to the already published 16 cases of PML in patients with MM. Additionally, this paper presents an analysis of cases from the United States Food and Drug Administration Adverse Event Report System database (n = 117) with a description of demographics and MM-specific therapies. Patients with MM, that developed PML, were treated with immunomodulatory drugs (97%), alkylating agents (52%), and/or proteasome inhibitors (49%). Prior to PML diagnosis, 72% of patients received two or more MM therapies. These results indicate that PML in MM is underreported and could be related to treatment with multiple immunosuppressive therapies rather than MM as a disease itself. Physicians should be aware of potential PML in the late stage of heavily treated MM patients.

Original languageEnglish
Article number1098930
JournalFrontiers in Neurology
Volume14
Number of pages6
ISSN1664-2295
DOIs
Publication statusPublished - 4. May 2023

Bibliographical note

Publisher Copyright:
Copyright © 2023 Jonasson, Antulov, Trøllund Pedersen and Sejbæk.

Keywords

  • case report
  • FAERS
  • immunosuppression
  • multiple myeloma
  • PML
  • progressive multifocal leukoencephalopathy

Fingerprint

Dive into the research topics of 'Progressive multifocal leukoencephalopathy in a patient with multiple myeloma: a case report and analysis of the FDA adverse event reporting system'. Together they form a unique fingerprint.

Cite this